Literature DB >> 3930598

Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

L A Rubin, C C Kurman, M E Fritz, W E Biddison, B Boutin, R Yarchoan, D L Nelson.   

Abstract

With the use of an enzyme-linked immunoabsorbent assay to measure soluble human interleukin 2 receptors (IL 2R), certain human T cell leukemia virus I (HTLV I)-positive T cell lines were found to spontaneously release large quantities of IL 2R into culture supernatants. This was not found with HTLV I-negative and IL 2 independent T cell lines, and only one of seven B cell-derived lines examined produced small amounts of IL 2R. In addition to this constitutive production of soluble IL 2R by certain cell lines, normal human peripheral blood mononuclear cells (PBMC) could be induced to release soluble IL 2R by plant lectins, the murine monoclonal antibody OKT3, tetanus toxoid, and allogeneic cells. Such activated cells also expressed cellular IL 2R measurable in detergent solubilized cell extracts. The generation of cellular and supernatant IL 2R was: dependent on cellular activation, rapid, radioresistant (3000 rad), and inhibited by cycloheximide treatment. NaDodSO4-polyacrylamide gel electrophoresis analysis of soluble IL 2R released from either the HTLV I-positive T cell line HUT 102B2 or normal phytohemagglutinin-activated PBMC demonstrated molecules of apparent Mr = 35,000 to 40,000, and 45,000 to 50,000, respectively, somewhat smaller than the mature surface receptor on these cells. The release of soluble IL 2R appears to be a characteristic marker of T lymphocyte activation and might serve an immunoregulatory function during both normal and abnormal cell growth and differentiation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930598

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  259 in total

1.  Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers.

Authors:  K Araki; K Harada; K Nakamoto; M Shiroma; T Miyakuni
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 2.  Cytokine receptors: structure and signal transduction.

Authors:  B M Foxwell; K Barrett; M Feldmann
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

3.  Evaluation of serum levels of tumour necrosis factor-alpha (TNF-alpha) and soluble IL-2 receptor (sIL-2R) and CD4, CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment.

Authors:  L A Santana-Blank; M Castes; M E Rojas; F Vargas; D Scott-Algara
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

4.  Serum soluble CD4, CD8 and IL-2R levels in adult acute myeloid leukemia in remission.

Authors:  Y Iizuka; M Aiso; T Ohshima; S Sawada; T Horie
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 5.  Cytokines, receptors, and inhibitors.

Authors:  G Gehr; T Braun; W Lesslauer
Journal:  Clin Investig       Date:  1992-01

6.  Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.

Authors:  J E Crabtree; L D Juby; R V Heatley; A J Lobo; D W Bullimore; A T Axon
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

7.  Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease.

Authors:  Y R Mahida; A Gallagher; L Kurlak; C J Hawkey
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

8.  Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis.

Authors:  P Airò; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

9.  Early lymphocyte activation molecule defined by the monoclonal antibody MLR-3: biochemical and functional studies.

Authors:  D Delia; C Traversari; D Ballinari; G Cattoretti; E Fontanella; N Polli; G Della Porta
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

10.  TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors:  E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.